Novel CAR-T for Glioblastoma Induced ‘Dramatic’ Responses in Early Trial
A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study. In the first-in-human trial, three patients with recurrent glioblastoma who were treated with CARv3-TEAM-E T cells experienced “dramatic and rapid” tumor regression within days of receiving a single intraventricular infusion, reported Marcela […]
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning
The FDA has identified more cases of secondary T-cell malignancies following treatment with chimeric antigen receptor (CAR) T-cell therapies, cases that led the agency to demand new boxed warnings on approved agents in the class. With about 27,000 doses of the six B-cell maturation antigen (BCMA)- or CD19-directed CAR-T products having been administered in the […]
‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. — Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here. CAR T-cell therapy is not yet ready for clinical practice, but enrolling patients in the growing number of clinical trials can help […]
Base-Edited CAR-T Product ‘Potent’ in Relapsed Childhood T-Cell ALL
The use of base editing to generate universal off-the-shelf chimeric antigen receptor (CAR) T cells in patients with relapsed T-cell acute lymphoblastic leukemia (ALL) should be further investigated based on promising interim results from a phase I study. In one of three patients — a 13-year-old girl who had relapsed T-cell ALL after allogeneic stem […]
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma
CHICAGO — Patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) in the second line for early relapsed or refractory large B-cell lymphoma had significantly longer overall survival (OS) than those treated with standard care, according to an analysis of the ZUMA-7 trial. At a median follow-up of 47.2 months […]
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma
In relapsed or refractory follicular lymphoma, treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta) was associated with better outcomes compared with currently available therapies, a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials suggested. Overall response rate (ORR) was higher, and both progression-free survival (PFS) and overall survival (OS) were […]
Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia
Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (ALL), a first-in-human clinical trial showed. After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation […]
Slow Going With CAR T-Cell Therapy for Solid Tumors
Almost 4 years after the first chimeric antigen receptor (CAR) T-cell therapies received FDA approval, the transformative impact of the treatment on refractory hematologic malignancies has yet to translate into the field of solid tumors. The increased molecular complexity of solid tumors and lack of good antigen targets have coalesced into a formidable roadblock for […]
Potential new CAR-T cell therapy for multiple myeloma
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet. “CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person’s own immune system by engineering […]